Evaluate the Potential for New Products within the Diabetes Market.

DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c42504) has announced the addition of Commercial Insight: Antidiabetics - Patent Expiries and Cost Containment Initiatives Balanced by Pipeline Products to their offering.

The diabetes epidemic has contributed to growth in the antidiabetics market over the past few years. Since the prevalence of diabetes continues to increase, the market will further expand. While early therapy is dominated by generically available agents, and the later stages by insulin, the number of unmet needs in the diabetes treatment warrants that novel agents will have a place in the market.

Scope of this title:

--Country specific event-driven sales forecasts for the period 2006-15 in the US, Japan, France, Germany, Italy, Spain and the UK, and a Global overview

--Patient potential and prescribing trends overview of the antidiabetics market based on historical sales data and future key events

--Profiles of the country and market specific issues which will impact future sales in the market including generic erosion and class switching 

--Case studies presenting the role that novel agents are likely to play and the balance between issues and opportunities in the diabetes market

Highlights of this title:

--Demographic trends will lead to increasing patient population. The antidiabetics market is set to continue increasing, driven by the dramatic increase in the prevalence of diabetes in the major markets. Additionally, the rising age of the population across all developed regions is creating an increased burden on health service providers and payers.

--The highest selling drug classes in the antidiabetics market are heavily genericized and thus will not generate the revenues needed for growing the market. Additionally, TZDs, one of the most lucrative classes, will face patent expiries in the coming decade. These events are expected to be counterbalanced by the introduction of novel agents.

--The diabetes market is characterized by high unmet need and treatment issues. However, these issues along with radical changes on the understanding of diabetes, have created an environment rich in opportunity. We expect that the growth of the diabetes market will be driven by the exchange of older, cheaper drugs for new more expensive agents.

Reasons to order your copy:

--Quantify the future size and scope of the diabetes market and potential for new products

--Analyze options to expand commercial potential through pursuit of new indications

--Formulate successful launch strategies in a highly competitive market

Products Mentioned:

--Humulin

--Humalog

--NovoLin

--NovoRapid/NovoLog

--Lantus

--TZDs market data

--Actos

--Avandia

--Sulfonylureas market data

--Amaryl

--Glucotrol XL

--Biguanide market data

--Glucophage and Glucophage XR

For more information visit http://www.researchandmarkets.com/reports/c42504

Source: Datamonitor